pd 173074 has been researched along with Nasopharyngeal Carcinoma in 1 studies
Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luan, H | 1 |
| Xu, Y | 1 |
| Fu, T | 1 |
| Luan, Y | 1 |
| Yuan, C | 1 |
1 other study available for pd 173074 and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
[FGFR1 selective inhibitor PD173074 can reduce proliferation and induce apoptosis of nasopharyngeal carcinoma].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans | 2014 |